A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer

Protocol No

MYTHIC-MYTX-011-01

Phase

I

Summary

This project is being done to determine the safety and tolerability, the best dose for future
development, as well as antitumor activity of a new antibody drug conjugate [ADC] called
MYTX-011.

Description

A Phase 1 Study of MYTX-011 in Subjects with NSCLC

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL